scispace - formally typeset
J

Jian Wang

Researcher at Guangzhou Medical University

Publications -  1831
Citations -  76717

Jian Wang is an academic researcher from Guangzhou Medical University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 94, co-authored 1018 publications receiving 57783 citations. Previous affiliations of Jian Wang include Northwestern University & Johns Hopkins University School of Medicine.

Papers
More filters
Journal ArticleDOI

Measurement of femoral posterior condylar offset and posterior tibial slope in normal knees based on 3D reconstruction

TL;DR: In this article, the posterior condylar offset (PCO) and posterior tibial slope (PTS) were measured and analyzed, as well as the correlation between them.
Posted ContentDOI

PALM-Seq: integrated sequencing of cell-free long RNA and small RNA

TL;DR: PALM-Seq provides an integrated, cost-effective and simple method to characterize the landscape of cell- free RNA, and can stimulate further progress in cell-free RNA study and usage.
Journal ArticleDOI

Disease causing poverty: adapting the Onyx and Bullen social capital measurement tool for China.

TL;DR: The Chinese health version of the Onyx-Bullen general social capital scale showed an adequate reliability and validity in a rural disease-causing poverty subpopulation in Shandong province, providing the first general, robust, consistent and reliable measure of social capital in China.
Journal ArticleDOI

Established pulmonary hypertension in rats was reversed by a combination of a HIF-2α antagonist and a p53 agonist.

TL;DR: In this paper, a combined treatment of Nutlin3a and HIF-2α antagonist, PT2385, was investigated for pulmonary hypertension (PH) based on the cell type-divergent regulation of p53 in pulmonary arterial smooth muscle cells and endothelial cells.
Journal ArticleDOI

The impact of COVID-19 on the cascade of care of HCV in the US and China

TL;DR: In this paper , the authors investigated the impact of the COVID-19 pandemic on the care continuum of HCV-infected patients in the US and China, and found that the proportion of patients undergoing HCV RNA testing during DAA treatment decreased from >81.7% before pandemic to 67.8% during the pandemic (P=0.006).